Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism.
Andrew B StergachisJonai Pujol-GiménezGergely GyimesiDaniel FusterGiusppe AlbanoMarina TroxlerJonathan PickerPaul A RosenbergAnn BerginJurriaan M PetersChristelle Moufawad El AchkarChellamani HariniShannon ManziAlexander RotenbergMatthias A HedigerLance H RodanPublished in: Annals of neurology (2019)
SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old SLC1A2-related epilepsy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019;85:921-926.